After Amazon and OpenAI, Synopsys (SNPS.US) also "looks to the East": plans to explore cooperation with Chinese AI laboratories on chip design technology
Global chip design software development leader Synopsys (SNPS.US) plans to explore cooperation with Chinese AI laboratories to improve the chip design process.
According to Zhihu Finance APP, Synopsys (SNPS.US), the global leader in chip design software development, plans to explore cooperation with Chinese AI labs to improve chip design processes. This move comes shortly after Synopsys signed multi-year agreements involving chip design technology with Amazon (AMZN.US) and OpenAI.
It is reported that Ravi Subramanian, Chief Product Officer of Synopsys, said the company is exploring partnerships with Chinese AI labs to develop similar tools for the Chinese market. As the demand for model training and deployment continues to grow, new AI-driven chip design tools are essential to keep up with this trend.
"We have a set of U.S. government regulations that we must comply with, and we will adhere to these regulations in any business expansion," Subramanian said. "We believe that China has its own growth momentum."
The agreement between Synopsys and OpenAI involves the development of GPT-Synopsys, an optimized dedicated model that utilizes Synopsys EDA tools to execute semiconductor design workflows.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Analyst Gu Jingci: Follow the trend and adapt flexibly
XRP Ledger adds account control feature, enabling enterprises to manage assets offline.
BUZZ - Goldman Sachs says the price cap on cancer drugs has limited impact on Indian hospitals
October 9 – Goldman Sachs pointed out that India's implementation of a 30% profit margin cap on non-scheduled anticancer drugs (link) will have limited impact on hospitals. The report states that, based on preliminary discussions with hospital chain groups, such drugs account for less than 5% of hospital revenue and 2% to 2.5% of operating profit. The report adds that hospitals can offset the losses by slightly adjusting service charges, such as administration fees. According to a government notice, an expert committee will finalize the list of drugs to be brought under regulation. Driven by the anticipated price cap, the share prices of Max Healthcare MAXE.NS, Apollo Hospitals APLH.NS, and Fortis Healthcare FOHE.NS rose by 1.6% to 2.5%. Previously, since September 30, these stocks had collectively declined by 11% to 11.5%. Year-to-date, FOHE and MAXE are down 11.7% and 14.8%, respectively, while APLH has risen by 11%. (To assist non-English speakers, Reuters provides automated translations of its reports into several other languages. Due to potential errors or missing context in automated translations, Reuters does not guarantee the accuracy of automatic translation texts and offers them solely for readers’ convenience. Reuters accepts no responsibility for any damage or loss caused by using these automated translation features.)
Adding insult to injury! Japanese electronics giant Nidec downgraded by UBS, stock price plunges over 9% and approaches an 11-month low
UBS has downgraded Nidec's rating from "Buy" to "Neutral" and lowered its target price from 2,800 yen to 2,400 yen, citing a more challenging market environment.
Crypto prices
More
